The lipid transporter FABP7 was repressed in both single and repeated dose group animals and in the recent study by Guzmán and colleagues LFABP was reported to be repressed during NAFLD [30]. This evidence concerns the gene FABP1 and metabolic dysfunction-associated steatotic liver disease.